Search research articles
Contact Us
Filters
Showing results (191-200 of 204) with videos related to
Page
of 21
Sort By:
The Journal of Urology
|
February 16, 2023
Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort
Peter S Kirk, Yair Lotan, Homayoun Zargar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 10, 2022
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
World Journal of Urology
|
August 9, 2021
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
Urologic Oncology
|
February 15, 2020
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
World Journal of Urology
|
September 28, 2022
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
Sarah M H Einerhand, Anna J Black, Homayoun Zargar, et al.
Clinical Genitourinary Cancer
|
May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes
Dimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.
Urologic Oncology
|
November 3, 2019
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy
Anna J Black, Homayoun Zargar, Kamran Zargar-Shoshtari, et al.
BJU International
|
October 1, 2021
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer
Dimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer
|
January 26, 2022
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
Rafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, et al.
European Urology
|
September 27, 2014
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Homayoun Zargar, Patrick N Espiritu, Adrian S Fairey, et al.
Page
of 21
Search research articles
Search
Showing results (191-200 of 204) with videos related to
Sort By:
Page
of 21
The Journal of Urology
|
February 16, 2023
Impact of Maximal Transurethral Resection on Pathological Outcomes at Cystectomy in a Large, Multi-institutional Cohort
Peter S Kirk, Yair Lotan, Homayoun Zargar, et al.
Journal of the National Comprehensive Cancer Network : JNCCN
|
August 10, 2022
NCCN Guidelines® Insights: Bladder Cancer, Version 2.2022
Thomas W Flaig, Philippe E Spiess, Michael Abern, et al.
World Journal of Urology
|
August 9, 2021
Association of age with response to preoperative chemotherapy in patients with muscle-invasive bladder cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
Urologic Oncology
|
February 15, 2020
Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer
David D'Andrea, Peter C Black, Homayoun Zargar, et al.
World Journal of Urology
|
September 28, 2022
Multicenter evaluation of neoadjuvant and induction gemcitabine-carboplatin versus gemcitabine-cisplatin followed by radical cystectomy for muscle-invasive bladder cancer
Sarah M H Einerhand, Anna J Black, Homayoun Zargar, et al.
Clinical Genitourinary Cancer
|
May 16, 2025
Response and Survival With Immune Checkpoint Inhibitor in Patients With Advanced Urothelial Carcinoma and Histology Subtypes
Dimitra Rafailia Bakaloudi, Rafee Talukder, Thomas Enright, et al.
Urologic Oncology
|
November 3, 2019
The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy
Anna J Black, Homayoun Zargar, Kamran Zargar-Shoshtari, et al.
BJU International
|
October 1, 2021
Association of prior local therapy and outcomes with programmed-death ligand-1 inhibitors in advanced urothelial cancer
Dimitrios Makrakis, Rafee Talukder, Leonidas N Diamantopoulos, et al.
Clinical Genitourinary Cancer
|
January 26, 2022
Response and Outcomes to Immune Checkpoint Inhibitors in Advanced Urothelial Cancer Based on Prior Intravesical Bacillus Calmette-Guerin
Rafee Talukder, Dimitrios Makrakis, Leonidas N Diamantopoulos, et al.
European Urology
|
September 27, 2014
Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer
Homayoun Zargar, Patrick N Espiritu, Adrian S Fairey, et al.
Page
of 21